• Entered into a collaboration with NIDA to develop intranasal naloxone for reversal of opioid overdose
  • Executed a global licensing agreement with Adapt Pharma in exchange for development and sales milestones plus royalties
  • Established a research license with Aegis Therapeutics for its proprietary delivery enhancement agent, Intravail®